Although fewer patients are undergoing cytoreductive nephrectomy as systemic treatments for renal cell carcinoma improve, the modality still has a vital role to play in the treatment paradigm—even in the modern age of immune checkpoint inhibitors.
Wolfgang Fendler, MD, discusses the rationale for creating the 68Ga-PSMA-11 PET in prostate cancer.
Jonathan W. Goldman, MD, health sciences clinical instructor, Department of Medicine, and Hematology/Oncology member, Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program, UCLA, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer (NSCLC).
Alexandra Drakaki, MD, discusses the design of the MORPHEUS-mUC trial in advanced/metastatic urothelial carcinoma.
Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the steps that can be taken to reduce potential exposure to coronavirus disease 2019 (COVID-19).
Wolfgang Fendler, MD, discusses the utility of 68Ga-PSMA-11 PET in prostate cancer.
Richard S. Finn, MD, the burst of available treatment options, the ongoing hunt for actionable biomarkers, and the importance of multidisciplinary care in hepatocellular carcinoma.
Sara A. Hurvitz, MD, discusses the need for additional research with fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.
Jonathan W. Goldman, MD, discusses the current landscape of biomarker-driven lung cancer.
Jonathan W. Goldman, MD, discusses targeted therapy options for patients with EGFR-, ALK-, and ROS1-mutated non–small cell lung cancer.
Sara A. Hurvitz, MD, Neelima Denduluri, MD, and Madelaine Kuiper, MSN, RN, discuss the rise of HER2-targeted therapies and their implications on the field.
Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the evolution of treatment in metastatic HER2-positive breast cancer.
Sara A. Hurvitz, MD, discusses treatment options for patients with HER2-positive metastatic breast cancer.
Madelaine Kuiper, MSN, RN, discusses the adverse event of interstitial lung disease, which can occur in patients with HER2-positive metastatic breast cancer who have received fam-trastuzumab deruxtecan-nxki.
Sarah A. Hurvitz, MD, medical oncologist, medical director, Clinical Research Unit for University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the findings in the DESTINY-Breast01 trial of patients with HER2-positive metastatic breast cancer.
Joshua P. Sasine, MD, PhD, discusses the challenges in predicting a patient’s individual benefit with CAR T-cell therapy in hematologic malignancies.
Richard S. Finn, MD, professor of clinical medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles (UCLA), and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA, discusses the rationale for the phase III KEYNOTE-240 trial in hepatocellular carcinoma (HCC).
Joshua P. Sasine, MD, PhD, spotlights some of the strategies under investigation to improve the safety and efficacy of CAR T-cell therapy in hematologic malignancies.
Joshua P. Sasine, MD, PhD, clinical instructor of medicine, hematologist, and oncologist, University of California, Los Angeles, discusses new developments with CAR T-cell therapy.
Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses the indications for the FDA-approved PARP inhibitors in recurrent ovarian cancer.
Gottfried E. Konecny, MD, shares the known aspects of PARP inhibition in recurrent ovarian cancer.
Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses toxicity associated with neratinib in the treatment of patients with HER2-positive breast cancer.
Sara A. Hurvitz, MD, discusses recent updates in the paradigm and promising therapeutic strategies on the horizon for patients with HER2-positive metastatic breast cancer.
Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the first- and second-line standards of care in HER2-positive breast cancer.
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the promise of immunotherapy in the treatment of patients with stage III unresectable non–small cell lung cancer.
Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses immune-related adverse events (irAEs) in melanoma.
Edward B. Garon, MD, discusses the landscape of EGFR-targeted therapy in non–small cell lung cancer.
Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the role of pertuzumab in HER2-positive breast cancer.
Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses the potential for combination immunotherapy and radiation in the treatment of patients with melanoma.
Endocrine therapy, commonly used for lengthy periods in the adjuvant treatment of patients with breast cancer, does not have a detrimental effect on cognitive function in survivors of early-stage disease.
